NasdaqGS:GRALBiotechs
What GRAIL (GRAL)'s Narrowed Q1 Loss And Revenue Growth Means For Shareholders
GRAIL, Inc. has reported its first-quarter 2026 results, with sales of US$39.83 million and revenue of US$40.79 million, alongside a net loss of US$93.19 million and basic and diluted loss per share from continuing operations of US$2.29, all reflecting improvement versus the same period a year earlier.
The combination of rising revenue and a smaller net loss suggests early benefits from GRAIL’s efforts to scale its multi-cancer early detection business while tightening cost control.
We’ll...